

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number  
**WO 03/074054 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/436**,  
47/14, 47/44, 31/4353

30096 (US). **YEN, Shau-Fong** [US/US]; 1295 North  
Druid Hills Road, Atlanta, GA 30319 (US).

(21) International Application Number: PCT/EP03/02156

(74) Agents: **GROS, Florent** et al.; Novartis AG, Corporate  
Intellectual Property, Patent & Trademark Department,  
CH-4002 Basel (CH).

(22) International Filing Date: 3 March 2003 (03.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/361,515 4 March 2002 (04.03.2002) US  
60/409,275 9 September 2002 (09.09.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH,  
PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT,  
UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): **NO-  
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel  
(CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH**  
[AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT).

**Published:**  
— with international search report  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BABIOLE  
SAUNIER, Maggy** [FR/FR]; 16 rue des champs, F-68130  
Jettingen (FR). **BIZEC, Jean-Claude** [FR/FR]; 12, rue Pe-  
tit-Landau, F-68440 Habsheim (FR). **WONG, Michelle,  
Pik-Han** [US/US]; 3308 Crossfield Way, Duluth, GA

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: OPTHALMIC COMPOSITION COMPRISING ASCOMYCIN

(57) Abstract: This invention relates to topical ophthalmic compositions comprising an ascomycin e.g. for the treatment of inflam-  
matory diseases such as blepharitis.



**WO 03/074054 A1**

## OPHTHALMIC COMPOSITION COMPRISING ASCOMYCIN

This invention relates to topical ophthalmic compositions comprising an ascomycin, e.g. for treatment of inflammatory diseases such as blepharitis.

Under "ascomycin" is to be understood ascomycin itself or a derivative, antagonist, agonist or analogue thereof, e.g. a compound of the FK 506 class.

Preferred ascomycins for use in the present invention include FK506 or a derivative, antagonist, agonist or analogue of FK506, which retain the basic structure and modulate at least one of the biological properties (for example immunological properties) of FK506 such as described in e.g. EP 184162, EP 315978, EP 323042, EP 423714, EP 427680, EP 465426, EP 474126, WO 91/13889, WO 91/19495, EP 484936, EP 532088, EP 532089, EP 569337, EP 626385, WO 93/5059 and the like; 33-epi-chloro-33-desoxy-ascomycin as disclosed in Example 66a in EP 427680 (hereinafter referred to as Compound A); {[1E-(1R,3R,4R)]1R,4S,5R,6S,9R,10E,13S,15S,16R,17S,19S,20S}-9-ethyl-6,16, 20-trihydroxy-4-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methylvinyl]-15,17-dimethoxy-5,11,13,19-tetramethyl-3-oxa-22-aza-tricyclo[18.6.1.0(1,22)]heptacos-10-ene-2,8,21,27-tetraone as disclosed in Examples 6d and 71 in EP 569 337 (hereinafter referred to as Compound B); and {1R,5Z,9S,12S-[1E-(1R,3R,4R)],13R,14S,17R,18E, 21S,23S,24R,25S,27R}17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-aza-tricyclo[22.3.1.0(4,9)] octacos-5,18-diene-2,3,10,16-tetraone, also known as 5,6-dehydro-ascomycin as disclosed in Example 8 in EP 626 385 (hereinafter referred to as Compound C); imidazolylmethoxyascomycin, as disclosed in Example 1 and as compound of formula I in WO 97/08182 (hereinafter referred to as Compound D); 32-O-(1-hydroxyethylindol-5-yl)ascomycin, also known as Indolyl-ASC or L-732 531 as disclosed in Transplantation 65 (1998) 10-18, 18-26, on page 11, Figure 1 (hereinafter referred to as Compound E); or (32-deoxy-32-epi-N1-tetrazolyl)ascomycin, also known as ABT-281 as disclosed in J. Inv. Derm. 112 (1999), 729-738, on page 730, Figure 1 (hereinafter referred to as Compound F).

- 2 -

FK 506, Compounds A, B, C, D, E, and F are preferred ascomycins, more preferred are Compounds A, B, and C, especially Compound A. Particularly preferred is Compound A.

Ascomycins have a variety of useful pharmacological actions, e.g. treatment of blepharitis, and may be administered topically. However, inter alia because of their physicochemical properties, e.g. high molecular weight and lipophilicity the ascomycins have posed problems for topical administration. Furthermore due to the sensitivity of the delicate eye tissues, only ophthalmically acceptable components may be employed in ophthalmic compositions.

Formulations, e.g. in form of an ointment, for application to the skin comprising ascomycins have been described e.g. in EP 474126 or EP 1135163. However, due to the irritation potential of some of the components used, these ointments may not be topically applied to the eye.

Applicants have now found that ophthalmic compositions comprising an ascomycin and a carrier comprising a medium chain fatty acid triglyceride and/or isopropyl myristate are highly efficient and well tolerated by the ocular tissue.

Preferred compositions of said kind comprise 33-epi-chloro-33-desoxy-ascomycin.

The active agent may be in suspension, e.g. partially in suspension in the vehicle. Preferably the active agent is however dissolved, e.g. partially dissolved, in the vehicle.

If the active agent is suspended, it may preferably be used in a micronized form. The suspension may contain particles of ascomycin of from 5, e.g. from 10, to about 90, preferably to about 25 microns in diameter. The particles of the ascomycin may be produced in conventional manner, e.g. by grinding or milling. In case the active agent exists in different polymorphic or pseudo-polymorphic forms, the thermodynamic stable form is preferably used in a suspension type formulation.

The active agent is e.g. present in the compositions of this invention in an amount of from 0.01 to 5% by weight, e.g. 0.05 to 3% by weight, e.g. from 0.1 to 2% by weight, e.g. from about 0.2 to about 1% by weight based on the total weight of the composition.

- 3 -

The carrier comprises isopropyl myristate or a medium chain triglyceride or a mixture thereof.

For the purposes of this application isopropyl myristate means a compound comprising not less than 90 percent of isopropyl tetradecanoate together with variable amounts of other fatty acid isopropyl esters.

Isopropyl myristate is preferably used in amounts from 1 to 20%, more preferably from 1 to 15, e.g. from about 2 to about 8% by weight based on the total weight of the composition.

Medium chain fatty acid triglycerides are preferably C<sub>6</sub> to C<sub>12</sub> fatty acid triglycerides, e.g. as known and commercially available under the trade name Acomed<sup>®</sup>, Myritol<sup>®</sup>, Captex<sup>®</sup>, Neobee<sup>®</sup>M5F, Miglyol<sup>®</sup>810, Miglyol<sup>®</sup>812, Mazol<sup>®</sup>, Sefsol<sup>®</sup>860, Sefsol<sup>®</sup>870. Especially preferred is the product Miglyol<sup>®</sup>812. Such medium chain fatty acid triglycerides are usually obtained from the oil extracted from the hard, dried fraction the endosperm of *Cocos nucifera* L. or from the dried endosperm of *Elaeis guineensis* Jaqu. They consist of a mixture of triglycerides of saturated fatty acids, mainly of caprylic acid and of capric acid, and contain not less than 95 percent of saturated fatty acids with 8 and 10 carbon atoms.

The medium chain fatty acid triglycerides may be present in an amount of 1 to 80% by weight based on the total weight of the composition, preferably about 10 to about 55% by weight.

Preferred compositions according to the invention include compositions which are in the form of an ointment and compositions which are in the form of an emulsion, in particular an oil-in-water emulsion.

The compositions according to the invention may therefore comprise a carrier which further comprises an ointment base. Suitable ointment bases include, for instance, ophthalmically acceptable oil and fat bases, such as

- (a) natural wax e.g. white bees wax, carnauba wax, wool wax (wool fat), purified lanolin, anhydrous lanolin,
- (b) petroleum wax e.g. solid paraffin, microcrystalline wax,

- 4 -

- (c) hydrocarbons e.g. liquid paraffin, white petrolatum (e. g. white Protopet®), yellow petrolatum, or
- (d) combinations thereof.

The above mentioned oil and fat bases are described, for instance, in the British Pharmacopoeia, Edition 2001, or in the European Pharmacopoeia, 3<sup>rd</sup> Edition.

The ointment base may be present in an amount from 1 to about 95% by weight based on the total weight of the composition, e. g. 40 to 95% by weight. A preferred range for the percentage of ointment base is 45 to 90% by weight based on the total composition.

The ointment compositions according to the present invention may further comprise some water, preferably in an amount of less than 10% by weight based on the total amount of composition.

The ointment type compositions of the present invention may further comprise ophthalmically acceptable surfactants/emulsifiers.

The ophthalmic compositions of the instant invention include also compositions wherein the carrier further comprises water and an emulsifier instead of the ointment base.

Water may preferably be present in these compositions in amounts of 60 to 90% by weight, e.g. 70 to 85% by weight.

The emulsifier is preferably an ethoxylated C<sub>16</sub>-C<sub>18</sub>alkyl carboxylic acid (CAS Registry No. 68989-61-7). Corresponding emulsifiers are available under names like Pegoxol 7 stearate, Dion 37, Tefose 63, Tefose 70 or Stearox SP9 etc and exhibit in particular a good ocular tolerance. The emulsifier is used in amounts as required, e.g. 0.5 to 10% by weight, preferably 1 to 5% by weight.

The emulsifier may be accompanied by suitable co-emulsifiers, for example Lauroyl Macrogolglycerides, which are mixtures of mono-, di- and triesters of glycerol and lauric acid

- 5 -

and mono- and diesters of macrogols (polyethylene glycols) having a mean molecular weight of e. g. between 300 and 1500. Suitable amounts range for example from 0.5 to 10% by weight, preferably 1 to 5% by weight.

The compositions of the present invention may further comprise an ophthalmically acceptable preservative. Suitable preservatives include

- (a) a quaternary ammonium compound such as e.g. benzalkonium chloride (N-benzyl-N-(C<sub>8</sub>-C<sub>18</sub>-alkyl)-N,N-dimethylammonium chloride), benzoxonium chloride, benzethonium chloride, cetrimide (hexadecyl-trimethylammonium bromide), sepazonium chloride, cetylpyridinium chloride, domiphen bromide (Bradosol®) or the like,
- (b) alkyl-mercury salts of thiosalicylic acid, such as e.g. thiomersal, phenylmercuric nitrate, phenylmercuric acetate or phenylmercuric borate,
- (c) parabens, such as e.g. methylparaben or propylparaben,
- (d) alcohols, such as e.g. chlorobutanol, benzyl alcohol or phenyl ethyl alcohol,
- (e) biguanide derivatives, such as e.g. chlorohexidine or polyhexamethylene biguanide,
- (f) sodium perborate,
- (g) imidazolidinyl urea as known and commercially available under the trade name Germa<sup>®</sup>II,
- (h) sorbic acid,
- (i) stabilized oxychloro complexes such as known and commercially available under the trade name Purite<sup>®</sup>,
- (k) polyglycol-polyamine condensation resins, such as known and commercially available e.g. under the trade name Polyquart<sup>®</sup> from Henkel KGaA,
- (l) stabilized hydrogen peroxide generated from a source of hydrogen peroxide for providing an effective trace amount of resultant hydrogen peroxide, e.g. sodium perborate tetrahydrate, and/or
- (m) a mixture of any components (a) to (l).

Preferred preservatives are quaternary ammonium compounds, in particular benzalkonium chloride, cetrimide and phenyl ethyl alcohol. Where appropriate, a sufficient amount of preservative is added to the ophthalmic composition to ensure protection against secondary contaminations during use caused by bacteria and fungi, e.g. benzalkonium chloride and/or

- 6 -

cetrimide are present in an amount of about 0.001-0.02%, or phenyl ethyl alcohol is present in an amount of about 0.05 to 1%.

The compositions of the present invention, in particular the emulsion-type compositions, may also comprise a suitable amount, e. g. 1 to 10 % by weight, of a thickening agent, for example a suitable glycerol monostearate or a mixture of mainly glycerol monostearate together with variable amounts of di- and triacylglycerols like for instance Glycerol Monostearate 40-55, e.g. Geleol<sup>®</sup>, which is a mixture of 40 to 55% by weight of monoacylglycerols, 30 to 45% by weight of the diacylglycerols and 5 to 15% by weight of triacylglycerols obtained by partial glycerolysis of vegetable oils mainly comprising triacylglycerols of palmitic and/or stearic acid.

The compositions of the present invention may further comprise ophthalmically acceptable complexing agents such as

- a) disodium-ethylenediamine tetraacetate, ethylenediamine tetraacetic acid (EDTA),
- b) chelating agents having phosphonic acid or phosphonate groups, preferably organophosphonates, particularly amino tri(lower alkylene phosphonic acids) such as those known and commercially available from Monsanto Company, St. Louis, under the trade name Dequest<sup>®</sup>, or the like,
- c) cyclodextrins, e.g.  $\alpha$ -,  $\beta$ - or  $\gamma$ -cyclodextrin, e.g. alkylated, hydroxyalkylated, carboxy-alkylated or alkyloxycarbonyl-alkylated derivatives, or mono- or diglycosyl- $\alpha$ -,  $\beta$ - or  $\gamma$ -cyclodextrin, mono- or dimaltosyl- $\alpha$ -,  $\beta$ - or  $\gamma$ - cyclodextrin or panosyl-cyclodextrin, e.g. such as known and commercially available under the trade name Cavamax<sup>®</sup> or Cavasol<sup>®</sup> from Wacker Chemie, or
- d) a mixture of components a) to c).

The compositions of the present invention may further comprise antioxidants such as ascorbic acid, acetylcysteine, cysteine, sodium hydrogen sulfite, butylated hydroxyanisole, butylated hydroxytoluene or alpha-tocopherol acetate.

The compositions of the present invention may further comprise ophthalmically acceptable stabilizers such thiourea, thiosorbitol, sodium dioctyl sulfosuccinate or monothioglycerol.

- 7 -

The compositions of the present invention may further comprise a buffer such as acetate, ascorbate, borate, hydrogen carbonate / carbonate, citrate, gluconate, lactate, phosphate, propionate and TRIS (tromethamine) buffers. Tromethamine and borate buffer are preferred buffers. The amount of a buffer added is, for example, that necessary to ensure and maintain a physiologically tolerable pH range. The pH range is typically in the range of from 5 to 9, preferably from 6 to 8.5 and more preferably from 6.5 to 8.2.

It will be appreciated that although the excipients have been described above by reference to a particular function any particular excipient may have alternative or multiple functions, e.g. cyclodextrin or a mixture of cyclodextrins may act as e.g. stabilizer, complexing agent and/or solubilizer.

Information on the properties, specifications and characteristics of the excipients are described e.g. in standard texts such as Fiedler, H.P.; 1996; Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete; Editio Cantor Verlag Aulendorf (Germany), and Kibbe, A.H.; 2000; Handbook of Pharmaceutical Excipients, a joint publication of Pharmaceutical Press, London (UK), and American Pharmaceutical Association, Washington (US) as well as manufacturers' brochures, the contents of which are incorporated herein by reference.

Preferably, the compositions of the present invention are free of components such as perfumes or colorants.

Preferred compositions of the present invention consist essentially of an ascomycin, a medium chain triglyceride, an ointment base and a preservative.

The compositions of the present invention are stable, as indicated by conventional tests, e.g. under stressed conditions, such as a temperature cycling test at 5 to 30°C or 40°C if relevant, or several months, e.g. 1 to 12 months, at 30°C. A suitable temperature cycle test may be carried out for instance in the following way: the samples are kept 12 hours at 5°C and then 12 hours preferably at 30°C or 40°C if relevant (depending on the melting point of the tested ointments) for several month. The device type is for instance a Temperature Test Cabinet CTS T-40/25.



- 8 -

The ophthalmic compositions of the present invention may be prepared in conventional manner e.g. by mixing the preferably gamma-irradiated ascomycin powder with the appropriate excipients, e.g. by mixing the gamma-irradiated ascomycin powder with sterile filtered medium chain triglyceride, part of the ointment bases, e.g. the wool fat and/or liquid paraffin, and additional oil phase, if present, and ball mill the ascomycin in the liquid medium and subsequently aseptically add the ascomycin containing liquid medium to the matrix containing sterile preservative and remaining part of the ointment bases, e.g. white petrolatum.

It is also well possible, for example, to dissolve the ascomycin in preheated medium chain triglyceride, and to add the molten ointment base with the preservative. Thereafter a final sterile filtration through a 0.22 micron filter is performed,

Alternatively, the ascomycin may be dissolved e.g. in heated white petrolatum. The mixture may be filtered through a 0.2 micron filter, e.g. Durapore<sup>®</sup> membrane filter, and be allowed to cool and subsequently form a suspension. The suspension may be further ball milled to uniformly disperse the ascomycin.

The emulsion-type compositions may also be prepared in conventional manner, e.g. by dissolving the preferably gamma-irradiated ascomycin powder with the sterile filtered oily phase, in particular the medium chain triglyceride, adding the emulsifier and/or co-emulsifier and dispersing said mixture in an appropriate quantity of sterile water using conventional emulsification devices, e.g. a high-speed stirrer or an ultrasonic generator etc.

The compositions according to the invention are useful in the treatment of inflammatory diseases, especially blepharitis e.g. chronic blepharitis, e.g. seborrhoeic blepharitis or allergic blepharitis, or staphylococcal blepharitis.

In another aspect the present invention provides a composition as defined above for use in the treatment of inflammatory diseases, especially blepharitis e.g. chronic blepharitis, e.g. seborrhoeic blepharitis or allergic blepharitis, or staphylococcal blepharitis.

- 9 -

In another aspect the present invention provides a method for treating inflammatory diseases, especially blepharitis, e.g. chronic blepharitis, e.g. seborrhoeic blepharitis or allergic blepharitis, or staphylococcal blepharitis, comprising topically administering a composition as defined above to the skin of a patient in need thereof.

In another aspect the present invention provides the use of a composition as defined above in the preparation of a medicament for topically administering to the eye, e.g. on the skin of the eyelid or upon the ocular surfaces of the eye, of a patient in need thereof.

In yet another aspect the present invention provides the use of a composition as defined above in the preparation of a medicament for the treatment of inflammatory diseases, especially blepharitis e.g. chronic blepharitis, e.g. seborrhoeic blepharitis or allergic blepharitis, or staphylococcal blepharitis.

The utility of the compositions according to the invention can be observed in standard clinical tests such as the test set out below.

One animal test comprises a modified Draize test on three albino rabbits wherein the ocular tolerability after a single dose instillation of 50 microlitres of compositions of the present invention on eyelid or the ocular surface is shown for the 15 minutes after application then after 1, 2 and 7 days. The tolerability was based on visual examination considering the following parameters: discomfort as judged by blinking or partial/complete closure of the eye, duration of discomfort, discharge, redness of conjunctiva (palpebral and bulbar conjunctiva), chemosis of conjunctiva (swelling), degree of opacity of cornea and area of cornea involved, and pathological influence upon iris.

The compositions of the invention are found to be effective, well tolerated and allow a long-term treatment of patients, e.g. of those suffering from chronic blepharitis.

The exact amount of the ascomycin and of the composition to be administered depends on several factors, for example the desired duration of treatment and the rate of release of the ascomycin. Satisfactory results are obtained in larger mammals, e.g. humans, with the local

- 10 -

application upon the eyelid to be treated or upon the ocular surfaces of the eye of a 0.01 to 5% by weight concentration of the ascomycin once or several times a day.

The following Examples illustrate the invention in more detail.

Example 1 to 5 (ointments)

Formulation	Ex. 1	Ex. 2	Ex. 3	Ex. 4	Ex. 5
Compound A <sup>1)</sup>	0.3-0.5	0.3-0.5	0.3-0.5	0.3-0.5	0.5
Miglyol 812 <sup>1)</sup>	50	50	50	50	50
Phenyl ethyl alcohol <sup>1)</sup>	0.5	0.5	-	-	-
Benzalkonium chloride <sup>1)</sup>	-	-	0.010	0.015	0.010
Wool fat <sup>1)</sup>	-	5	-	5	5
Liquid paraffin <sup>1)</sup>	-	-	-	-	-
White petrolatum <sup>1)</sup>	ad 100	ad 100	ad 100	ad 100	ad 100
Preservative Efficacy Test with preservative	USP <sup>3)</sup> Failed	USP <sup>3)</sup> Failed	EurP "A" <sup>4)</sup> Failed	EurP "A" <sup>4)</sup> Failed	EurP "A" <sup>4)</sup> Failed
Without preservative					
Ocular tolerance	moderate	moderate	moderate	moderate	moderate

<sup>1)</sup> amounts in weight percent

<sup>3)</sup> complies with the criteria for antimicrobial effectiveness according to the US Pharmacopeia

<sup>4)</sup> complies with the criteria "A" for antimicrobial effectiveness according to the European Pharmacopeia, chapter 5.1.3

Example 6 to 9 (ointments)

Formulation	Ex. 6	Ex. 7	Ex. 8	Ex. 9
Compound A <sup>1)</sup>	1.0	0.2	1.0	0.5-1.0
Miglyol 812 <sup>1)</sup>	10	20	-	50
Isopropyl myristate	-	-	3.1	-
Phenyl ethyl alcohol <sup>1)</sup>	0.5	-	0.5	0.5
Benzalkonium chloride <sup>1)</sup>	-	0.015	0.010	-
Wool fat <sup>1)</sup>	-	6	-	10
Microcrystalline wax	-	-	12.9	13
Liquid paraffin <sup>1)</sup>	-	10	33.5	22
White petrolatum <sup>1)</sup>	ad 100	ad 100	ad 100	ad 100
Preservative Efficacy Test with preservative	EurP "A" <sup>4)</sup> Failed	EurP "A" <sup>4)</sup> Failed	-	-
Without preservative			-	-
Ocular tolerance	moderate	good	-	-

1), 3), 4) cf. Examples 1 to 5

Example 10 (emulsion-type composition)

Composition	0.3% Compound A 15.0% Medium chain triglycerides 2% Lauroyl Macrogloglycerides 3% Pegoxol 7 stearate (Tefose 63) 3% Glycerol monostearate 40-55 (Geleol) 1.25% Propylene glycol 0.5% Phenyl ethyl alcohol ad 100% Water
Appearance/ process	Solution

amounts in weight percent

- 12 -

Compound A is dissolved in the oily phase comprising the medium chain triglycerides. Then the water phase is added and the mixture is homogenized with an Ultra Turax homogenizer at 11000 rpm for about 30 seconds and finally stirred at 700 rpm for about 15 minutes.

The resulting composition exhibits a moderate ocular tolerance as proved in an animal model and meets the requirements as defined as European Pharmacopeia (Eur. Ph.) criteria B for ophthalmic preparations. The emulsion is stable at room temperature for at least 10 month (no phase separation occurs).

Composition / Example	11	12
Ingredients in wt. %		
Compound A	0.30	0.30
Miglyol 812	50.00	50.00
White petrolatum	42.70	43.05
Microcrystalline wax	6.00	6.00
Benzalkonium chloride	-	-
Chlorobutanol	-	-
Phenylethyl alcohol*	1.00	0.5
Methylparaben	-	0.1
Propylparaben	-	0.05
Appearance	White ointment	White ointment

Claims

1. Ophthalmic composition comprising an ascomycin and a carrier comprising a medium chain triglyceride and/or isopropyl myristate.
2. Composition according to claim 1 wherein said ascomycin is 33-epi-chloro-33-desoxy-ascomycin.
3. Composition according to claim 1 or 2 wherein said carrier further comprises an ointment base.
4. Composition according to claim 1 or 2 wherein said carrier comprises a medium chain triglyceride.
5. Composition according to claim 1 or 2 wherein said carrier comprises isopropyl myristate.
6. Composition according to claim 4 wherein said carrier further comprises water and an emulsifier.
7. Composition according to claim 6, wherein said emulsifier is an ethoxylated C<sub>16</sub>-C<sub>18</sub>alkyl carboxylic acid.
8. Composition according to claim 6 wherein said emulsifier is Pegoxol 7 stearate (Tefose 63).
9. Composition according to claim 6 in form of an oil-in-water emulsion.
10. Composition according to claim 1 or 2 in form of an ointment.
11. Composition of claim 1 – 10 further comprising a preservative.

- 14 -

12. Composition of claim 11, wherein said preservative is selected from the group consisting of
- (a) a quaternary ammonium compound such as e.g. benzalkonium chloride (N-benzyl-N-(C<sub>8</sub>-C<sub>18</sub>-alkyl)-N,N-dimethylammonium chloride), benzoxonium chloride, benzethonium chloride, cetrimide (hexadecyl-trimethylammonium bromide), sepazonium chloride, cetylpyridinium chloride, domiphen bromide (Bradosol<sup>®</sup>) or the like,
  - (b) alkyl-mercury salts of thiosalicylic acid, such as e.g. thiomersal, phenylmercuric nitrate, phenylmercuric acetate or phenylmercuric borate,
  - (c) parabens, such as e.g. methylparaben or propylparaben,
  - (d) alcohols, such as e.g. chlorobutanol, benzyl alcohol or phenyl ethyl alcohol,
  - (e) biguanide derivatives, such as e.g. chlorohexidine or polyhexamethylene biguanide,
  - (f) sodium perborate,
  - (g) imidazolidinyl urea as known and commercially available under the trade name Germal<sup>®</sup>II,
  - (h) sorbic acid,
  - (i) stabilized oxychloro complexes such as known and commercially available under the trade name Purite<sup>®</sup>,
  - (k) polyglycol-polyamine condensation resins, such as known and commercially available e.g. under the trade name Polyquart<sup>®</sup> from Henkel KGaA,
  - (l) stabilized hydrogen peroxide generated from a source of hydrogen peroxide for providing an effective trace amount of resultant hydrogen peroxide, e.g. sodium perborate tetrahydrate, and/or
  - (m) a mixture of any components (a) to (l).
13. Composition of claim 12, wherein said preservative is selected from benzoxonium chloride, sodium perborate, phenyl ethyl alcohol, sorbic acid, Purite<sup>®</sup> and/or mixtures thereof.
14. Composition of claim 13, wherein said preservative is benzoxonium chloride.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/02156

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/436 A61K47/14 A61K47/44 A61K31/4353

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EP 1 074 255 A (FUJISAWA PHARMACEUTICAL CO) 7 February 2001 (2001-02-07)</p> <p>paragraph '0001!</p> <p>paragraph '0010!</p> <p>paragraph '0033!</p> <p>paragraph '0042!</p> <p>paragraph '0066!</p> <p>claim 6</p> <p>example 4</p> <p style="text-align: center;">--- -/-</p>	1-3,5, 10,11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

3 July 2003

Date of mailing of the international search report

14/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

VON EGCELKRAUT, S



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/02156

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 13249 A (SANDOZ AG ;SCHMOOK FRITZ (AT); POPP XUE PING (CH); JACKMAN MARTIN) 9 May 1996 (1996-05-09) page 1, paragraph 1 page 2, line 5 - line 10 page 5, line 2 - line 3 page 6, line 16 -page 8, line 12 page 9, paragraph 1 examples 1,2,8-11,13-20 ----	1-6,9-12
Y	WO 95 05176 A (ALCON LAB INC) 23 February 1995 (1995-02-23) page 1, paragraph 1 page 6, paragraph 1 examples 1,2 ----	1-13
Y	EP 0 406 791 A (FUJISAWA PHARMACEUTICAL CO) 9 January 1991 (1991-01-09) page 3, line 1 -page 4, line 39 ----	1-13
X	EP 0 474 126 A (FUJISAWA PHARMACEUTICAL CO) 11 March 1992 (1992-03-11) cited in the application example 18 ----	1-5,10
X	WO 00 32234 A (NOVARTIS AG) 8 June 2000 (2000-06-08) page 1, paragraph 1 page 1, last paragraph -page 3, paragraph 4 page 6, paragraph 5 -page 7, paragraph 1 page 15, line 10 -page 16, line 22 claims 1,7,8 & EP 1 135 163 A 26 September 2001 (2001-09-26) cited in the application ----	1-6,9,10
A	US 5 496 811 A (AVIV HAIM ET AL) 5 March 1996 (1996-03-05) column 1, paragraph 1 column 5, paragraph 3 ----	1-11
A	EP 0 737 478 A (OREAL) 16 October 1996 (1996-10-16) page 2, paragraph 1 page 4, line 4 - line 6 ----	6-8
A	WO 00 66122 A (UENO SEIYAKU OYO KENKYUJO KK ;UENO RYUJI (US)) 9 November 2000 (2000-11-09) page 1, line 4 - line 8 page 3, line 37 -page 4, line 1 -----	1-11

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/02156

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1074255	A	07-02-2001	AU 749475 B2	27-06-2002
			AU 3537299 A	16-11-1999
			BR 9910336 A	25-09-2001
			CA 2326222 A1	04-11-1999
			EP 1074255 A1	07-02-2001
			HU 0104452 A2	28-03-2002
			NO 20005399 A	26-10-2000
			NZ 507345 A	20-12-2002
			CN 1307475 T	08-08-2001
			WO 9955332 A1	04-11-1999
			PL 343627 A1	27-08-2001
			TR 200003108 T2	21-02-2001
			US 2002061907 A1	23-05-2002
WO 9613249	A	09-05-1996	AT 214593 T	15-04-2002
			AU 714254 B2	23-12-1999
			AU 3845195 A	23-05-1996
			AU 5833699 A	06-01-2000
			BR 9509530 A	14-10-1997
			CA 2200966 A1	09-05-1996
			CN 1401325 A	12-03-2003
			CN 1162259 A ,B	15-10-1997
			CZ 9701232 A3	13-08-1997
			CZ 290219 B6	12-06-2002
			DE 19581804 T0	22-01-1998
			DE 69525957 D1	25-04-2002
			DE 69525957 T2	14-11-2002
			DK 786986 T3	29-04-2002
			WO 9613249 A1	09-05-1996
			EP 1147766 A2	24-10-2001
			EP 0786986 A1	06-08-1997
			ES 2173978 T3	01-11-2002
			FI 971018 A	18-04-1997
			GB 2308546 A ,B	02-07-1997
			HU 77140 A2	02-03-1998
			JP 10508588 T	25-08-1998
			NO 971951 A	25-04-1997
			NZ 295170 A	25-02-1999
			NZ 331824 A	28-01-2000
			PL 319599 A1	18-08-1997
			PL 185320 B1	30-04-2003
			PT 786986 T	31-07-2002
			SI 786986 T1	30-06-2002
			SK 52097 A3	10-09-1997
			US 2001031769 A1	18-10-2001
			GB 2327610 A ,B	03-02-1999
			PL 184908 B1	31-01-2003
			RU 2181592 C2	27-04-2002
WO 9505176	A	23-02-1995	AT 196734 T	15-10-2000
			AU 680539 B2	31-07-1997
			AU 7560594 A	14-03-1995
			CA 2146006 A1	23-02-1995
			DE 69426062 D1	09-11-2000
			DE 69426062 T2	22-03-2001
			EP 0664705 A1	02-08-1995
			ES 2152329 T3	01-02-2001
			JP 8502759 T	26-03-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/02156

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505176 A		WO 9505176 A1	23-02-1995
		US 5705510 A	06-01-1998
EP 0406791 A	09-01-1991	AT 117897 T	15-02-1995
		AU 635286 B2	18-03-1993
		AU 5864290 A	24-01-1991
		CA 2020431 A1	06-01-1991
		CN 1048496 A ,B	16-01-1991
		DE 69016515 D1	16-03-1995
		DE 69016515 T2	08-06-1995
		DK 406791 T3	27-03-1995
		EP 0406791 A2	09-01-1991
		ES 2066915 T3	16-03-1995
		GR 3014946 T3	31-05-1995
		HK 27097 A	06-03-1997
		IE 902413 A1	19-06-1991
		IL 94971 A	08-12-1995
		JP 2536248 B2	18-09-1996
		JP 3128320 A	31-05-1991
		KR 163035 B1	01-12-1998
		US 5770607 A	23-06-1998
EP 0474126 A	11-03-1992	AT 150304 T	15-04-1997
		AU 656145 B2	27-01-1995
		AU 8351591 A	12-03-1992
		CA 2050623 A1	05-03-1992
		CN 1059468 A ,B	18-03-1992
		DE 69125230 D1	24-04-1997
		DE 69125230 T2	10-07-1997
		DK 474126 T3	07-04-1997
		EP 0474126 A1	11-03-1992
		ES 2099112 T3	16-05-1997
		GR 3022883 T3	30-06-1997
		HK 1000006 A1	03-10-1997
		HU 59002 A2	28-04-1992
		IE 913085 A1	11-03-1992
		JP 2526752 B2	21-08-1996
		JP 5017481 A	26-01-1993
		PT 98862 A ,B	31-08-1992
		SG 46547 A1	20-02-1998
		RU 2079303 C1	20-05-1997
		US 5385907 A	31-01-1995
		ZA 9106983 A	27-05-1992
WO 0032234 A	08-06-2000	AU 1656900 A	19-06-2000
		BR 9915861 A	21-08-2001
		CA 2350884 A1	08-06-2000
		CN 1329507 T	02-01-2002
		CZ 20011908 A3	12-09-2001
		WO 0032234 A1	08-06-2000
		EP 1135163 A1	26-09-2001
		HU 0104413 A2	28-03-2002
		JP 2002531419 T	24-09-2002
		NO 20012624 A	09-07-2001
		PL 348750 A1	03-06-2002
		SK 7622001 A3	06-11-2001
		TR 200101547 T2	22-10-2001
		US 2001051650 A1	13-12-2001

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/02156

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5496811	A	05-03-1996	AT 191641 T	15-04-2000
			AU 680813 B2	14-08-1997
			AU 3432593 A	29-03-1994
			CA 2142103 A1	17-03-1994
			DE 69328368 D1	18-05-2000
			DE 69328368 T2	10-08-2000
			EP 0656779 A1	14-06-1995
			SG 49746 A1	15-06-1998
			WO 9405298 A1	17-03-1994
			ZA 9300069 A	04-08-1993
			JP 8508975 T	24-09-1996
EP 0737478	A	16-10-1996	FR 2732598 A1	11-10-1996
			DE 69613041 D1	05-07-2001
			DE 69613041 T2	13-09-2001
			EP 0737478 A1	16-10-1996
			US 6168809 B1	02-01-2001
WO 0066122	A	09-11-2000	AU 4142900 A	17-11-2000
			BR 0011225 A	19-03-2002
			CA 2372448 A1	09-11-2000
			CN 1353608 T	12-06-2002
			CZ 20013769 A3	13-03-2002
			EP 1173177 A1	23-01-2002
			HU 0200864 A2	29-07-2002
			WO 0066122 A1	09-11-2000
			JP 2002543132 T	17-12-2002
			NO 20015288 A	29-10-2001
			TR 200103119 T2	22-04-2002